BioTelemetry (BEAT) is a top acquisition target going into the new year. The company is the leading wireless medical device provider expanding on a booming niche, the mobile cardiac telemetry market. General cardiac monitoring is projected to exceed $30 billion within three years. At a market cap under $2 billion, BioTel would undoubtedly be a propitious acquisition target for companies higher on the food chain. Whether a buyout is in the stars or not, long-term exposure in BioTel will pay off in spades.
Source: BioTel investor presentation
The development of wireless mobile healthcare